Search results
Results from the WOW.Com Content Network
Novo Nordisk (NYSE: NVO) Q4 2024 Earnings Call ... we have returned DKK 64.3 billion to shareholders via dividends and share buyback during 2024. At the annual general meeting on 27th of March ...
Novo’s stock fell slightly in early December after a trial sponsored by Lilly found that patients who took Zepbound lost 20.2% of their body weight, on average, compared with just a 13.7% ...
Novo Nordisk stock has been ... the company's oral GLP-1 medication Rybelsus posted an impressive growth rate of 29% ... has an estimated 32% market share. By all accounts, Novo Nordisk is firing ...
And there's another thing they might find encouraging: At 27.4 times earnings today, Novo Nordisk stock costs barely one-third the P/E ratio of Novo's closest competitor in GLP-1 weight loss drugs ...
Meanwhile, today's massive sell-off in Novo Nordisk stock may be giving investors an unexpected second bite at the GLP-1 apple -- a chance to buy Novo stock at a price-to-earnings ratio of barely 29.
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that made the ...
For premium support please call: 800-290-4726 more ways to reach us
Should you buy Novo Nordisk stock right now? Novo Nordisk's price-to-earnings (P/E) ratio of 39.7 is far from cheap. By comparison, the average P/E for the S&P 500 is about 28.